This Month in JNM
=================


**Cardiac stem cell tracking:** Zhang and Wu review the basic principles, current techniques, and future prospects for in vivo stem cell cardiovascular imaging.  
</br> ***[Page 1916](http://jnm.snmjournals.org/lookup/volpage/48/1916?iss=12)***

**PET/CT in pediatric malignancies:** Federman and Feig offer the clinician's perspective on the status of functional/anatomic imaging in pediatric cancers and point to specific challenges, including the need for additional research and more refined protocols.  
</br> ***[Page 1920](http://jnm.snmjournals.org/lookup/volpage/48/1920?iss=12)***

**PET/CT in non-CNS pediatric cancers:** Tatsumi and colleagues compare the accuracy and efficacy of PET/CT and conventional imaging in evaluating young patients with non–central nervous system malignancies.  
</br> ***[Page 1923](http://jnm.snmjournals.org/lookup/volpage/48/1923?iss=12)*** 

![Figure1](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F1.medium.gif)

[Figure1](http://jnm.snmjournals.org/content/48/12/11A/F1)

**PET/CT for Ewing tumors:** Gerth and colleagues assess the relative advantages of PET/CT and PET alone in staging and restaging patients with Ewing tumor, with additional findings on the ability of the hybrid technique to detect new lesions.  
</br> ***[Page 1932](http://jnm.snmjournals.org/lookup/volpage/48/1932?iss=12)***

**18F-FDA PET in pheochromocytoma:** Timmers and colleagues report on patient studies designed to establish cutoff values for pathologic and physiologic adrenal gland tracer uptake in 6-18F-fluorodopamine PET localization of pheochromocytoma.  
</br> ***[Page 1940](http://jnm.snmjournals.org/lookup/volpage/48/1940?iss=12)*** 

![Figure2](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F2.medium.gif)

[Figure2](http://jnm.snmjournals.org/content/48/12/11A/F2)

**18F-FLT PET in gastric cancer:** Herrmann and colleagues evaluate the proliferation marker 18F-fluorothymidine for PET detection of gastric cancer and compare the resulting diagnostic accuracy with that of 18F-FDG PET.  
</br> ***[Page 1945](http://jnm.snmjournals.org/lookup/volpage/48/1945?iss=12)*** 

![Figure3](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F3.medium.gif)

[Figure3](http://jnm.snmjournals.org/content/48/12/11A/F3)

**Variable patient size and PET:** El Fakhri and colleagues assess whole-body 18F-FDG PET performance in lesion detection using a series of different acquisition and processing methods adjusted for patients of varying sizes and weights.  
</br> ***[Page 1951](http://jnm.snmjournals.org/lookup/volpage/48/1951?iss=12)*** 

![Figure4](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F4.medium.gif)

[Figure4](http://jnm.snmjournals.org/content/48/12/11A/F4)

**Metabolism vs. morphometry in AD:** Matsunari and colleagues compare the abilities of 18F-FDG PET and optimized voxel-based morphometry in discriminating between healthy individuals and those at progressive stages of Alzheimer's disease.  
</br> ***[Page 1961](http://jnm.snmjournals.org/lookup/volpage/48/1961?iss=12)***

**11C-Met PET normal references:** Coope and colleagues describe coregistration methods to facilitate interpretation of 11C-methionine PET images with reference to averaged normal uptake maps, allowing standardization of analysis and increased sensitivity to tumor infiltration.  
</br> ***[Page 1971](http://jnm.snmjournals.org/lookup/volpage/48/1971?iss=12)*** 

![Figure5](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F5.medium.gif)

[Figure5](http://jnm.snmjournals.org/content/48/12/11A/F5)

**D2 receptors and iNPH:** Nakayama and colleagues use 11C-raclopride PET to extend their studies of idiopathic normal pressure hydrocephalus, focusing on treatment with ventriculoperitoneal shunts and the contributions of dopamine receptors to associated pathophysiology.  
</br> ***[Page 1981](http://jnm.snmjournals.org/lookup/volpage/48/1981?iss=12)*** 

![Figure6](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F6.medium.gif)

[Figure6](http://jnm.snmjournals.org/content/48/12/11A/F6)

**Microvascular resistance in chronic infarct areas:** Marques and colleagues report on an H215O PET study comparing fractional flow reserve in infarct-related arteries and reference flow reserve in patients with chronic myocardial infarction.  
</br> ***[Page 1987](http://jnm.snmjournals.org/lookup/volpage/48/1987?iss=12)***

**Spironolactone and candesartan in CHF:** Kasama and colleagues investigate the effects of the angiotensin-receptor blocker candesartan alone and in combination with spironolactone in cardiac sympathetic nerve activity and left ventricular function in patients with congestive heart failure.  
</br> ***[Page 1993](http://jnm.snmjournals.org/lookup/volpage/48/1993?iss=12)***

**Nuclear imaging in CRT:** Henneman and colleagues provide an educational overview of the status of cardiac resynchronization therapy in heart failure, including a review of nuclear medicine techniques in initial assessment, evaluation of therapy, and prediction of outcomes.  
</br> ***[Page 2001](http://jnm.snmjournals.org/lookup/volpage/48/2001?iss=12)*** 

![Figure7](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F7.medium.gif)

[Figure7](http://jnm.snmjournals.org/content/48/12/11A/F7)

**Imaging mesenchymal stem cells:** Love and colleagues describe a triple-reporter system for bioluminescence and PET imaging to monitor human mesenchymal stem cell transplants and discuss the potential for translation to human studies with PET.  
</br> ***[Page 2011](http://jnm.snmjournals.org/lookup/volpage/48/2011?iss=12)*** 

![Figure8](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F8.medium.gif)

[Figure8](http://jnm.snmjournals.org/content/48/12/11A/F8)

**18F-F-CP PET for breast cancer:** Kesner and colleagues examine the biodistribution of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts and report on the potential of this technique in predicting the resistance of tumors to cyclophosphamide therapy.  
</br> ***[Page 2021](http://jnm.snmjournals.org/lookup/volpage/48/2021?iss=12)*** 

![Figure9](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F9.medium.gif)

[Figure9](http://jnm.snmjournals.org/content/48/12/11A/F9)

**Antisense imaging:** Liu and colleagues investigate whether a 99mTc-radiolabeled antisense oligonucleotide targeting human telomerase reverse transcriptase mRNA can be used for in vivo imaging of telomerase activity in carcinomas.  
</br> ***[Page 2028](http://jnm.snmjournals.org/lookup/volpage/48/2028?iss=12)*** 

![Figure10](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F10.medium.gif)

[Figure10](http://jnm.snmjournals.org/content/48/12/11A/F10)

**Math model of dynamic 18F-FDG PET data:** Ferl and colleagues report on a novel method for plasma time–activity curve estimation in murine small-animal PET studies, based on a model of tracer kinetics in blood, muscle, and liver.  
</br> ***[Page 2037](http://jnm.snmjournals.org/lookup/volpage/48/2037?iss=12)***

**11C-lactate PET and myocardial imaging:** Herrero and colleagues use l-3-11C-lactate PET to acquire noninvasive quantitative measurements of myocardial lactate metabolism in animals.  
</br> ***[Page 2046](http://jnm.snmjournals.org/lookup/volpage/48/2046?iss=12)*** 

![Figure11](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F11.medium.gif)

[Figure11](http://jnm.snmjournals.org/content/48/12/11A/F11)

**Tracer uptake in brain abscesses:** Salber and colleagues compare uptake of the amino acid tracer 18F-FET with that of 3H-MET and 3H-DG in brain abscesses in rats to assess the suitability of 18F-FET imaging for distinguishing between inflammation and gliomas.  
</br> ***[Page 2056](http://jnm.snmjournals.org/lookup/volpage/48/2056?iss=12)*** 

![Figure12](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F12.medium.gif)

[Figure12](http://jnm.snmjournals.org/content/48/12/11A/F12)

**LAT-mediated amino acid uptake in tumors:** Haase and colleagues provide evidence that 18F-labeled amino acids that accumulate in tumors via system L amino acid transporters represent an important class of imaging agents for in vivo PET visualization of tumors.  
</br> ***[Page 2063](http://jnm.snmjournals.org/lookup/volpage/48/2063?iss=12)***

**Radiation dosimetry of 11C-PBR28:** Brown and colleagues report on studies estimating human radiation doses for this recently developed radioligand, which shows promise in imaging peripheral benzodiazepine receptors.  
</br> ***[Page 2072](http://jnm.snmjournals.org/lookup/volpage/48/2072?iss=12)***

**Radiation safety with 90Y-microspheres:** Gulec and Siegel describe radiation safety issues associated with the intrahepatic arterial administration of 90Y-resin or 90Y-glass microspheres, including dose estimates and posttherapy management.  
</br> ***[Page 2080](http://jnm.snmjournals.org/lookup/volpage/48/2080?iss=12)***

#### ON THE COVER

This schematic for the noninvasive imaging of stem cell fate in myocardium shows the 4 different techniques currently in use for tracking stell cells in vivo, including magnetic particle labeling, radionuclide labeling, quantum dot labeling, and reporter gene labeling. 

![Figure13](http://jnm.snmjournals.org/https://jnm.snmjournals.org/content/jnumed/48/12/11A/F13.medium.gif)

[Figure13](http://jnm.snmjournals.org/content/48/12/11A/F13)

See page [1917](http://jnm.snmjournals.org/lookup/volpage/48/1916?iss=12).